What is Inato?
Founded in 2015 and headquartered in Paris, France, Inato operates a sophisticated platform aimed at assisting biopharmaceutical companies in expanding their patient pools for clinical trials. By addressing a critical bottleneck in drug development, Inato enables faster and more efficient trial execution. The company's technology is designed to connect researchers with a broader and more diverse range of potential participants, thereby accelerating the path to new therapies. This strategic focus positions Inato as a key enabler within the health tech and biopharma sectors.
How much funding has Inato raised?
Inato has raised a total of $34M across 1 funding round:
Series A
$34M
Series A (2023): $34M with participation from Serena Ventures, The Obvious, Fly Ventures, and Cathay Innovation
Key Investors in Inato
Serena Ventures
Serena Ventures, founded by Serena Williams, focuses on early-stage investments in companies with diverse leadership, particularly those in sectors like health & wellness and technology. They provide not only capital but also mentorship and network expansion opportunities.
The Obvious
The Obvious Corp is a creative and design firm that transforms client ideas into compelling marketing and communications materials. While their specific investment focus isn't detailed, their involvement suggests a strategic partnership or advisory role.
Cathay Innovation
Cathay Innovation is a global venture capital firm that invests in multi-stage startups making a positive impact through technology, with a portfolio spanning finance, healthcare, and autonomous driving.
What's next for Inato?
With the recent influx of major strategic investment, Inato is poised for accelerated growth and expansion. The substantial capital raised will likely be directed towards enhancing its platform capabilities, broadening its market reach, and forging new partnerships within the biopharmaceutical industry. This funding round, characterized as enterprise-level, suggests Inato is moving into a significant scaling phase, aiming to solidify its position as a leader in clinical trial patient recruitment solutions and further drive innovation in healthcare research.
See full Inato company page
